Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-05-13 Purchase |
2021-05-17 07:02 am |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
5,925,925 | $1.35 | $7,999,999 | 7,804,778 (Indirect) |
View |
| 2020-11-17 Purchase |
2020-11-19 4:40 pm |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. Director 10% Owner |
60,000 | $50 | $3,000,000 | 155,262 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-05-30 Option Award |
2024-06-03 4:15 pm |
N/A 2034-05-29 |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner |
10,000 | $0 | 10,000 (Direct) |
View |
| 2023-06-06 Option Award |
2023-06-08 4:44 pm |
N/A 2033-06-05 |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner |
10,000 | $0 | 10,000 (Direct) |
View |
| 2022-06-06 Exercise(A) |
2023-02-28 12:29 pm |
N/A N/A |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
1,030 | $5 | 1,434,958 (Indirect) |
View |
| 2022-06-06 Exercise(A) |
2023-02-28 12:29 pm |
2015-09-01 2022-09-01 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
1,030 | $0 | 1,434,958 (Indirect) |
View |
| 2022-10-21 Exercise(A) |
2023-02-28 12:23 pm |
N/A N/A |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
47,999 | $5.94 | 1,485,168 (Indirect) |
View |
| 2022-10-21 Exercise(A) |
2023-02-28 12:23 pm |
2018-12-27 2022-12-27 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
47,999 | $0 | 1,485,168 (Indirect) |
View |
| 2022-06-16 Exercise |
2023-02-28 12:21 pm |
N/A N/A |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
2,211 | $5 | 1,437,169 (Indirect) |
View |
| 2022-06-16 Exercise |
2023-02-28 12:21 pm |
2015-09-01 2022-09-01 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
2,211 | $0 | 1,437,169 (Indirect) |
View |
| 2022-11-29 Exercise |
2022-11-30 4:40 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner |
7,176 | $0.0001 | 1,226,412 (Indirect) |
View |
| 2022-11-29 Exercise |
2022-11-30 4:40 pm |
N/A 2023-10-07 |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner |
7,176 | $0 | 1,226,412 (Indirect) |
View |
| 2022-10-21 Exercise |
2022-10-25 4:57 pm |
N/A N/A |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
47,999 | $5.94 | 1,481,927 (Indirect) |
View |
| 2022-10-21 Exercise |
2022-10-25 4:57 pm |
2018-12-27 2022-12-27 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
47,999 | $0 | 1,481,927 (Indirect) |
View |
| 2022-06-06 Exercise |
2022-08-25 3:25 pm |
N/A N/A |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
1,030 | $5 | 1,433,928 (Indirect) |
View |
| 2022-06-06 Exercise |
2022-08-25 3:25 pm |
2015-09-01 2022-08-31 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
1,030 | $0 | 1,433,928 (Indirect) |
View |
| 2022-06-15 Option Award |
2022-06-17 08:26 am |
N/A 2032-06-15 |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 3:36 pm |
N/A 2032-06-08 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
10,000 | $0 | 10,000 (Indirect) |
View |
| 2022-06-01 Option Award |
2022-06-03 4:30 pm |
N/A 2032-05-31 |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner |
8,293 | $0 | 8,293 (Direct) |
View |
| 2021-03-25 Exercise(A) |
2021-06-09 1:46 pm |
N/A N/A |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
1,030 | $5 | 1,431,717 (Indirect) |
View |
| 2021-03-25 Exercise(A) |
2021-06-09 1:46 pm |
2014-07-27 2021-07-27 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
1,030 | $0 | 1,431,717 (Indirect) |
View |
| 2021-03-25 Exercise |
2021-06-09 1:42 pm |
N/A N/A |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
2,211 | $5 | 1,443,928 (Indirect) |
View |
| 2021-03-25 Exercise |
2021-06-09 1:42 pm |
2014-07-27 2021-07-27 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
2,211 | $0 | 1,443,928 (Indirect) |
View |
| 2021-06-07 Option Award |
2021-06-09 1:42 pm |
N/A 2031-06-06 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
10,000 | $0 | 1,443,928 (Indirect) |
View |
| 2021-06-01 Option Award |
2021-06-03 5:34 pm |
N/A 2031-05-31 |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner |
8,293 | $0 | 8,293 (Direct) |
View |
| 2021-05-19 Option Award |
2021-05-20 4:10 pm |
N/A 2031-05-19 |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2021-03-24 Exercise |
2021-04-22 5:18 pm |
N/A N/A |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
1,030 | $5 | 1,465,199 (Indirect) |
View |
| 2021-03-24 Exercise |
2021-04-22 5:18 pm |
2014-07-27 2021-07-27 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
1,030 | $0 | 1,465,199 (Indirect) |
View |
| 2021-01-22 Equity Swap |
2021-01-26 5:07 pm |
N/A N/A |
Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director |
1,576,881 | $0 | 0 (Indirect) |
View |
| 2020-06-17 Option Award |
2020-06-19 6:38 pm |
N/A 2030-06-17 |
Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director |
17,000 | $0 | 17,000 (Direct) |
View |
| 2020-06-08 Option Award |
2020-06-10 6:41 pm |
N/A 2030-06-07 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
10,000 | $0 | 10,000 (Direct) |
View |
| 2020-05-20 Option Award |
2020-05-22 4:10 pm |
N/A 2030-05-20 |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
20,000 | $0 | 20,000 (Direct) |
View |